The European Commission has approved an extension to the indications of Bavarian Nordic’s mpox vaccine, Imvanex, to include adolescents aged from 12 to 17 years, in a move intended to help health authorities in Africa and elsewhere tackle the spread of the disease.
EU OKs Imvanex Vaccine In Younger People To Help Tackle Mpox Spread In Africa
The World Health Organization has also prequalified the Bavarian Nordic vaccine to enable broader and timely access.
More from Europe
• By
While the pharma industry appears to be exempt from US tariffs imposed by President Trump, a member of the UK House of Lords says the details are unknown and warned that uncertainty “leads to less investment” in business as a whole.
• By
The EU Clinical Trials Information System has achieved primary registry designation in the International Clinical Trials Registry Platform in a move that is expected to reduce regulatory burden for companies and help them lower compliance costs by aligning with publication requirements in medical journals.
• By
The UK government has listened to industry concerns about high clawback rates under the voluntary scheme and will review it in June in a bid to resolve the issue and “move on to bigger and more important things,” health secretary Wes Streeting says.
• By
England’s health technology assessment institute, NICE, is looking to “reimagine” its evaluation process with the help of AI, rather than just using this technology to speed up its existing processes.
More from Middle East & Africa
• By
A newly published draft implementing act sets out the procedural rules for the joint scientific consultations that are foreseen by the EU’s Health Technology Assessment Regulation.
• By
The World Health Organization has also prequalified the Bavarian Nordic vaccine to enable broader and timely access.
• By
Companies marketing pharmaceutical products in Saudi Arabia are being urged to prepare for upcoming mandatory pharmacoeconomic assessments to demonstrate the added value of their drugs over existing treatments.